Signal/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-re-scored-composite-v2.md

# Signal CGM — Re-Scored Composite Model v2
### Asset Sale Primary (50%) · Pilot Secondary (30%) · SaaS Tertiary (20%)
### MA + Medicaid First Proof-of-Concept Payer Scope
### STTIL Solutions LLC | April 2026

---

## Priority Weights

| Objective | Weight | Rationale |
|-----------|--------|-----------|
| Asset sale / strategic handoff | 50% | Fastest path to capital realization |
| Pilot validation | 30% | Evidence from pilot raises asset sale price |
| SaaS ICP potential | 20% | Informs asset buyer's deployment ROI |

---

## Scoring Assumption Audit

### Asset Sale — Why These Weights

**Distribution reach (30%):** An asset sale to a platform touching 500+ suppliers
is worth orders of magnitude more than one touching one. This is the dominant
criterion because it determines the multiplier on the asset's downstream value.

**Strategic need (25%):** Pull motion (buyer has documented gap) is more reliable
than push motion (we convince buyer they need it). NikoHealth's CGM intelligence
gap is documented and real. Billing companies' MA plan-rule complexity is felt daily.

**Price ceiling (20%):** Current $25K–$60K is priced for a direct supplier buyer.
A platform vendor or MSO can justify 3–5× that. Weight at 20% because price ceiling
is contingent on strategic need — no need, no premium.

**Speed to close (15%):** Closing faster is better but not at the expense of deal
size. Pursue fast-close candidates in parallel with long-cycle targets.

**Build vs. buy (10%):** Modifier on other criteria. Accelerates a deal that
already has strategic need; doesn't create one where those are absent.

### Pilot — Why These Weights

**Data accessibility (25%):** Pilot must generate measurable denial rate change.
Requires structured CGM billing data with denial reason codes — not spreadsheets.

**Cooperation likelihood (20%):** Active partner engagement multiplies data access
value. Poor data + high cooperation still generates useful qualitative signal.

**Signal quality (20%):** Pilot must generalize to the asset buyer's customer base.
Single Florida supplier = anecdote. Billing company across 3 MACs = evidence.

**PHI/compliance overhead (20%):** High-overhead pilot = delayed pilot. Given CB
2028 window, compliance friction is a real timeline risk.

**Feedback loop speed (15%):** A 30–60 day feedback cycle is acceptable;
6 months is not viable given the urgency window.

---

## Individual Segment Scores — MA + Medicaid Scope Applied

### NikoHealth-Type Platform Vendor

**Asset Sale Sub-Score:**
| Criterion | Wt | Score | Note |
|-----------|-----|-------|------|
| Distribution reach | 30% | 10 | Serves exact buyer profile across hundreds of suppliers |
| Strategic need | 25% | 10 (+1) | MA+Medicaid scope widens the gap — no platform has plan-specific rules |
| Price ceiling | 20% | 9 | MA module = 3–5× current ask to a motivated platform buyer |
| Speed to close | 15% | 3 | Enterprise procurement: 4–8 months minimum |
| Build vs. buy | 10% | 8 (+1) | MA plan-rule maintenance is ongoing data work, not a sprint |
**Sub-score: 8.55**

**Pilot Sub-Score:**
| Criterion | Wt | Score | Note |
|-----------|-----|-------|------|
| Data accessibility | 25% | 10 | Best dataset: all supplier clients across all payers |
| Cooperation likelihood | 20% | 3 (−1) | Exposing own platform gap is sensitive under MA scope |
| Signal quality | 20% | 10 | Multi-supplier, multi-plan, multi-jurisdiction |
| PHI overhead | 20% | 7 | HIPAA infrastructure exists |
| Feedback speed | 15% | 4 | Enterprise review before data access |
**Sub-score: 7.10**

**SaaS ICP Score: 4.65**
**NikoHealth Composite: (8.55×0.50) + (7.10×0.30) + (4.65×0.20) = 7.34**

---

### Billing Company / DME RCM Outsourcer

**Asset Sale Sub-Score:**
| Criterion | Wt | Score | Note |
|-----------|-----|-------|------|
| Distribution reach | 30% | 7 | Serves 10–50 DMEPOS clients per firm |
| Strategic need | 25% | 9 (+1) | MA plan-specific PA rules are their most expensive unsolved problem |
| Price ceiling | 20% | 7 (+1) | $40K–$80K justified across 20+ clients under MA scope |
| Speed to close | 15% | 5 | Owner/managing partner: 60–90 day decision cycle |
| Build vs. buy | 10% | 7 | Not a tech company; will buy |
**Sub-score: 7.20**

**Pilot Sub-Score:**
| Criterion | Wt | Score | Note |
|-----------|-----|-------|------|
| Data accessibility | 25% | 10 | MA + Medicaid billing data across all clients — defines the advantage |
| Cooperation likelihood | 20% | 8 (+1) | MA complexity is their daily pain; highly motivated under this payer scope |
| Signal quality | 20% | 10 | Multi-supplier, multi-plan data |
| PHI overhead | 20% | 6 | HIPAA infrastructure exists; BAA manageable |
| Feedback speed | 15% | 6 | Fast initiation; first MA cycle data in 30 days |
**Sub-score: 8.20**

**SaaS ICP Score: 7.75 (+0.80 under MA scope — tool becomes a revenue line)**
**Billing Company Composite: (7.20×0.50) + (8.20×0.30) + (7.75×0.20) = 7.61**

---

### VGM Group / MSO

**Asset Sale Sub-Score:**
| Criterion | Wt | Score | Note |
|-----------|-----|-------|------|
| Distribution reach | 30% | 10 | Thousands of small-to-mid DMEPOS suppliers nationally |
| Strategic need | 25% | 6 (−1) | MA/Medicaid are plan-specific problems outside VGM's policy leverage |
| Price ceiling | 20% | 7 | $75K–$150K justified as member benefit |
| Speed to close | 15% | 3 | 6–12 month committee procurement |
| Build vs. buy | 10% | 8 | VGM endorses/buys tools, does not build |
**Sub-score: 7.15**

**Pilot Sub-Score:**
| Criterion | Wt | Score | Note |
|-----------|-----|-------|------|
| Data accessibility | 25% | 3 | No supplier billing data; must recruit members |
| Cooperation likelihood | 20% | 5 | Conceptual support; cannot drive participation |
| Signal quality | 20% | 3 (−1) | Member base skews rural/small; less MA density |
| PHI overhead | 20% | 4 | VGM as intermediary adds complexity layer |
| Feedback speed | 15% | 3 | Slow: member recruitment + separate BAAs |
**Sub-score: 3.60**

**SaaS ICP Score: 5.30**
**VGM Composite: (7.15×0.50) + (3.60×0.30) + (5.30×0.20) = 5.72**

---

### Mid-Size Independent Supplier

**Asset Sale Sub-Score:**
| Criterion | Wt | Score | Note |
|-----------|-----|-------|------|
| Distribution reach | 30% | 1 | Single supplier; no scale |
| Strategic need | 25% | 6 (+1) | MA scope raises personal pain — daily multi-plan complexity |
| Price ceiling | 20% | 3 (+1) | MA ROI strengthens argument; still marginal for asset sale |
| Speed to close | 15% | 4 | Owner decision: 2–8 weeks if motivated |
| Build vs. buy | 10% | 3 | Cannot build; would subscribe not buy |
**Sub-score: 3.30**

**Pilot Sub-Score:**
| Criterion | Wt | Score | Note |
|-----------|-----|-------|------|
| Data accessibility | 25% | 7 | Structured in Brightree/NikoHealth; needs 50+ MA patients for signal |
| Cooperation likelihood | 20% | 8 | Billing manager engages daily; highly motivated |
| Signal quality | 20% | 7 (−2) | Thin MA mix reduces cross-plan generalizability |
| PHI overhead | 20% | 5 | BAA: standard, manageable |
| Feedback speed | 15% | 8 | Monthly MA billing cycle; fast iteration |
**Sub-score: 6.95**

**SaaS ICP Score: 8.10 (+0.30 — MA complexity is their most expensive unsolved problem)**
**Mid-Size Supplier Composite: (3.30×0.50) + (6.95×0.30) + (8.10×0.20) = 5.36**

---

## Composite Ranking Summary (Base + MA/Medicaid Adjusted)

| Rank | Segment | Base Composite | MA+Med Adj | Final Score |
|------|---------|---------------|-----------|-------------|
| #1 | Billing company / DME RCM | 7.17 | +0.44 | **7.61** |
| #2 | NikoHealth-type platform | 7.22 | +0.12 | **7.34** |
| #3 | VGM Group / MSO | 5.98 | −0.26 | **5.72** |
| #4 | Mid-size independent supplier | 5.27 | +0.09 | **5.36** |

---

## The Sequencing Logic

The #1 and #2 positions are 0.27 points apart. This is not a clear winner —
it is a parallel tracks signal:

1. **Pilot with billing company first.** 60 days. Generates denial rate
   reduction data from real MA + Medicaid billing. Low cost.

2. **Use that evidence to close NikoHealth.** The pilot data makes the
   NikoHealth asset sale conversation 3× easier and likely 2× more valuable
   in price negotiation.

These tracks are mutually reinforcing, not competing.

**VGM is the correct follow-on distribution deal** after the NikoHealth asset
sale or billing company deployment — not the primary target during MA + Medicaid
proof-of-concept.

---

## MA + Medicaid: The Payer Complexity That Changes Everything

```
FFS Medicare: One ruleset per MAC jurisdiction (4 MACs nationally)
Medicare Advantage: 800+ plans, each with plan-specific PA rules
                    layered on top of CMS Part B baseline
Medicaid: 50 state rulesets, often MCO-layered within each state
          TRAP: Several states have moved CGM coverage to pharmacy-only
          (NY May 2024; others following) — verify before piloting
```

**Why this matters for NikoHealth:** Maintaining current MA plan-specific
PA rules across 800+ plans is ongoing data work, not engineering. A supplier
tool that owns this database has a moat that is expensive to replicate.

**Why this matters for billing companies:** They are already maintaining
these rules manually in someone's spreadsheet. The pain is personal and daily.

---

## Key Denial Quantification

| Metric | Value | Source |
|--------|-------|--------|
| CGM improper payment rate | 25.2% | CMS 2024 |
| Projected annual improper payments | $278.5M | CMS 2024 |
| Documentation failure share | 94.2% | CMS 2024 |
| No documentation at all | 67.6% | CMS 2024 |
| Insufficient documentation | 26.6% | CMS 2024 |
| MA DMEPOS appeal success (L2) | 63.9% | KFF 2024 |
| MA PA denial rate | 7.7% | KFF 2024 |
| Write-off rate on denied claims | ~63% | Derived from appeal ladder economics |
| Net revenue loss after appeals | ~20% of gross CGM billing | Derived |

---

## Sources
- [CMS 2024 CGM Improper Payments](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies)
- [KFF: MA 53M PA Determinations 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/)
- [MA Denial Spike — Medicare Rights Center](https://www.medicarerights.org/medicare-watch/2024/09/26/medicare-advantage-denials-increased-before-the-implementation-of-new-prior-authorization-rules)
- [Unequal DME/Pharmacy Enforcement — CMS Comment](https://downloads.regulations.gov/CMS-2025-0242-0025/attachment_1.pdf)
- [UHC/Synapse Health State Expansion](https://www.uhcprovider.com/en/resource-library/news/2025/synapse-health-manage-dme-orders.html)
- [OIG CGM Payments Exceeded Costs 2025](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/)
- [NY State Medicaid CGM Billing Update 2024](https://www.emedny.org/ProviderManuals/communications/billing_glucose_monitors_-_5-9-24.pdf)
- [NikoHealth vs Brightree 2026](https://coruzant.com/software/dme-and-hme-software-in-2026/)